Navigation Links
Cloud of smoke over Zyban

Can an anti-smoking drug be injurious to health? Pharma giant GlaxoSmithKline (GSK), under fire regarding its smoking cessation drug, Zyban, has risen in defence of its non-nicotine oral drug - in the wake of unproven reports in the UK, linking the drug to adverse reactions and deaths. //

Touted to be the world’s most successful smoking cessation drug, Zyban received a high decibel launch in India in June 2001. The cause for concern, however, was a safety update on the site of British regulatory body, Medicines Control Agency (MCA). The update, suggesting an unproven association between the tobacco-cessation drug and 57 deaths in the UK, spurred media-reports abroad casting a cloud over Zyban and subsequently causing a ripple effect in domestic circles.

Mr Kal Sundaram, GSK’s Director-Pharmaceuticals, told that regulatory bodies such as MCA of the UK and the FDA of the US have celared the drug and have said that “there were no reports directly linking the deaths to Zyban”. Zyban is a prescription drug and GSK would continue to sell it across world markets, he said. Endorsing the safety profile of Zyban, GSK said: “Death (the 57 reported deaths) was most commonly due to cardiovascular causes and where information on medical history was provided, most patients had a history of cardiovascular disease or risk factors for cardiovascular disease in addition to smoking.”

According to GSK reports in the UK, sales had slumped 34 per cent to 22 million pounds ($31 million) in the three months between October to September last year following media coverage of the reported deaths. Zyban, when launched, had come with its cautions saying: “For majority of smokers, side effects of Zyban are not a concern. Zyban is generally well tolerated. Side effects are mild and include dry mouth and insomnia.....should be used cautiously, if at all, in patients with seizure disorder and in those taking alcohol during treament.”
'"/>




Page: 1

Related medicine news :

1. Smokers Cloud Has A Silver Lining?
2. IMF considers Bird Flu to be a Dark Cloud
3. Half of worlds children are passive smokers - damning disclosure from WHO
4. Glaxo launches pills to help smokers quit in 7-12 weeks
5. Emotional trigger to smoke
6. Poor diet among smokers
7. Pregnant smokers could harm their child
8. Drinkers and smokers are at risk
9. A new method to help smokers quit
10. What makes young girls smoke
11. Poor diet among smokers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission for Health ... Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction in Oncology. ... distinction. ACHC provides a wide range of pharmacy accreditation services that assess the ...
(Date:4/28/2016)... ... April 28, 2016 , ... SyncDog, Inc. , ... leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s 6th annual Mobile First Conference ... will be MobileIron’s 6th Mobile First Conference and will feature immersive training, collaboration, ...
(Date:4/28/2016)... ... ... Baich had written poetry dating back to her childhood, but after several years without writing ... on a more spiritual tone. The desire to put the words on paper was very ... file it away. Friends would ask her how she wrote such wonderful poetry and her ...
(Date:4/28/2016)... ... , ... For the 10,000 Americans who turn 65 on any given day, ... well-being: mental health. Now, a new book—Staying Sharp For Dummies (Paper; ISBN: 978-1-119-18779-0; Available ... can include everything from honing your memory and managing stress to eating healthy foods ...
(Date:4/28/2016)... ... ... Boston Laser is now offering a novel treatment for Keratoconus following its approval ... of Riboflavin, a vitamin, to the cornea. This, combined with UV light, leads to ... the progression of keratoconus. , Keratoconus is the continuous thinning and alteration of the ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... a developer of a new generation of drugs ... overall survival results for Paclical/Apealea in the Phase ... patients with epithelial ovarian cancer. These preliminary results ... in combination with carboplatin versus Taxol in combination ...
(Date:4/27/2016)... SAN FRANCISCO , April 27, 2016 /PRNewswire/ ...  is expected to reach USD 2.06 billion by ... View Research, Inc. Increasing consumer awareness towards a ... over the next seven years.      ... Improper diet intake coupled with rising health treatment ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
Breaking Medicine Technology: